利伐沙班治疗静脉血栓疗效好吗？

It has a preventive effect on deep vein thrombosis that occurs after hip or knee replacement surgery, and it can also prevent pulmonary embolism that occurs after hip or knee replacement surgery. Is rivaroxaban effective in treating venous thrombosis?

The therapeutic effect of rivaroxaban in the treatment of venous thrombosis:

The phase III clinical study COMPASS of rivaroxaban shows that an intra-arterial dose of 2.5 mg twice a day plus aspirin 100 mg once a day can significantly reduce the composite risk of stroke, cardiovascular death and heart disease in patients with chronic coronary artery disease (CAD) or peripheral artery disease (PAD) by up to 24%.

This study compared this combination therapy with aspirin 100 mg once daily alone. Patients included in the study were already receiving treatment for hypertension, hyperlipidemia, and diabetes as recommended by the guidelines. The study also examined rivaroxaban 5 mg twice daily, but did not show a statistically significant difference in the primary endpoint.

The benefits of rivaroxaban are reflected in the composite efficacy endpoint and major adverse cardiovascular events (MACE). Rivaroxaban 2.5 mg twice a day plus aspirin 100 mg once a day significantly reduces the risk of stroke by 42% and reduces the risk of cardiovascular death by 22%. The treatment also reduced the risk of heart attack by 14%, but this result did not show a statistically significant difference.

The combination therapy showed a substantial 20% improvement in net clinical benefit, which was reached after weighing its effectiveness in reducing stroke, cardiovascular death and heart attack against the likelihood of the most serious bleeding events. The hazard ratio for all-cause death was 0.82 (95% CI 0.71-0.96; P=0.01). The incidence of bleeding was low, and although major bleeding increased, there was no significant increase in intracranial or fatal bleeding. And importantly, major adverse limb events and major amputations due to vascular factors were significantly reduced in patients with peripheral artery disease.